Stock listing

ASX:DXB Dimerix Limited Share Price

Home listing (ASX) of Dimerix Limited

Follow Dimerix Limited into a list and get an email when it puts out news.

Share price · ASX:DXB

$0.185 AUD 0.000 (0.0%)

Close on Nov 20, 2026

Past year -60.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.180 – $0.190 AUDNov 20, 2026
Volume
559,775 sharesNov 20, 2026
Market cap
$111.1M AUDAt the close on Nov 20, 2026 · price × 600.4M shares outstanding
52-week range
$0.158 – $0.665 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$177,022 AUDMedian day 621,128 shares · 2 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Dimerix Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:DXB · Home$0.185 AUD0.000 (0.0%)559,775$0.190$0.190$0.180$0.185Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:DXB · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.1850.0000.0%$0.190$0.190$0.180559,775
$0.185-0.010-5.1%$0.195$0.195$0.185413,982
$0.1950.0000.0%$0.195$0.200$0.190855,490
$0.195-0.005-2.5%$0.210$0.210$0.195600,338
$0.2000.0000.0%$0.200$0.210$0.200739,754
$0.200-0.015-7.0%$0.215$0.215$0.2001,265,783
$0.215-0.005-2.3%$0.210$0.225$0.2101,108,379
$0.2200.0000.0%$0.210$0.220$0.210487,944
$0.220+0.015+7.3%$0.210$0.220$0.205593,069
$0.205-0.005-2.4%$0.205$0.210$0.205413,216
$0.210+0.010+5.0%$0.200$0.222$0.2001,032,400
$0.200-0.010-4.8%$0.210$0.210$0.200411,563
$0.2100.0000.0%$0.210$0.210$0.205165,895
$0.2100.0000.0%$0.210$0.215$0.205636,778
$0.210-0.005-2.3%$0.215$0.220$0.210333,872
$0.215+0.010+4.9%$0.210$0.225$0.210462,081
$0.205+0.005+2.5%$0.210$0.215$0.200736,782
$0.2000.0000.0%$0.205$0.205$0.195178,868
$0.200+0.005+2.6%$0.200$0.200$0.19533,422
$0.195-0.010-4.9%$0.215$0.215$0.1951,061,694
$0.205-0.005-2.4%$0.200$0.210$0.200300,416
$0.210+0.005+2.4%$0.210$0.215$0.200260,743
$0.205-0.005-2.4%$0.205$0.215$0.205194,898
$0.210-0.010-4.5%$0.230$0.230$0.208692,566
$0.220+0.010+4.8%$0.210$0.225$0.210552,845
$0.2100.0000.0%$0.215$0.215$0.1951,137,925
$0.210-0.010-4.5%$0.215$0.220$0.210238,108
$0.2200.0000.0%$0.215$0.220$0.215272,987
$0.2200.0000.0%$0.240$0.240$0.218438,080
$0.2200.0000.0%$0.225$0.228$0.215325,000
$0.220-0.005-2.2%$0.225$0.230$0.220438,756
$0.225-0.005-2.2%$0.225$0.230$0.220638,201
$0.230-0.005-2.1%$0.240$0.240$0.225975,412
$0.235+0.010+4.4%$0.225$0.245$0.225830,659
$0.225-0.010-4.3%$0.230$0.230$0.225402,282
$0.235+0.005+2.2%$0.235$0.235$0.225525,796
$0.2300.0000.0%$0.235$0.235$0.225271,613
$0.230-0.005-2.1%$0.235$0.240$0.225387,718
$0.235+0.010+4.4%$0.235$0.235$0.225686,422
$0.225-0.010-4.3%$0.235$0.235$0.225605,478
$0.2350.0000.0%$0.240$0.240$0.2301,094,284
$0.235-0.005-2.1%$0.240$0.240$0.2301,414,555
$0.240+0.005+2.1%$0.240$0.240$0.235305,261
$0.235-0.010-4.1%$0.255$0.255$0.235927,640
$0.2450.0000.0%$0.245$0.255$0.2401,558,801
$0.245+0.005+2.1%$0.240$0.245$0.235286,203
$0.240+0.005+2.1%$0.245$0.245$0.230849,293
$0.235-0.005-2.1%$0.240$0.245$0.235817,578
$0.240-0.010-4.0%$0.250$0.275$0.240765,446
$0.2500.0000.0%$0.250$0.255$0.245810,805
$0.250-0.010-3.8%$0.270$0.270$0.2501,392,741
$0.260-0.010-3.7%$0.270$0.270$0.2601,125,101
$0.270-0.010-3.6%$0.275$0.280$0.270815,693
$0.280-0.005-1.8%$0.290$0.290$0.275899,948
$0.285-0.005-1.7%$0.305$0.310$0.2802,999,082
$0.2900.0000.0%$0.290$0.290$0.2900
$0.2900.0000.0%$0.290$0.290$0.2900
$0.290+0.010+3.6%$0.275$0.290$0.275408,682
$0.280+0.005+1.8%$0.280$0.280$0.2601,368,829
$0.275-0.015-5.2%$0.285$0.295$0.275572,986
$0.2900.0000.0%$0.295$0.295$0.285710,477
$0.290-0.025-7.9%$0.310$0.310$0.2901,791,495
$0.315+0.005+1.6%$0.305$0.315$0.305587,104
$0.3100.0000.0%$0.315$0.315$0.305696,317
$0.310-0.015-4.6%$0.325$0.330$0.3081,167,459
$0.325+0.030+10.2%$0.305$0.325$0.3002,234,026

Splits

6 splits since 1995 · ASX:DXB · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
1-for-14Consolidation
5-for-3Split
2-for-5Consolidation
14-for-11Split
26-for-25Split
Ticker
ASX:DXB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
ASX
Currency
AUD

What changed lately

Latest news

All Dimerix Limited news

Dimerix Limited on 6ix

Sector
Health care
Industry
Biotechnology
News releases
44 in the last 12 months · 248 in all · newest Nov 5, 2026 · oldest 2016
Decks
86 decks · latest Oct 23, 2026

Where Dimerix Limited is listed

ListingExchangeCountryCurrency
ASX:DXB · Home listing · This pageASXAustraliaAUD
OTC:SBMJFOTCUnited StatesUSD

Cash and shares

Sep 15, 2026 · Dimerix — ASX SMIDcaps Conference 2026

Shares outstanding
600,396,776

The slide these figures come from

Valuation

EV/sales 21.9× against a median of 68.3×: 4th lowest of 7 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$95.15M AUD
P/E
Loss
EV/sales
21.9×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
96.8%
Operating margin
−854.6%
Net margin
−685.3%
Debt to equity
Negative equity
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Dimerix Limited · ASX:DXBUS$73.52MUS$62.98Mn/a21.9×n/an/a−685.3%n/an/a
Recce Pharmaceuticals Ltd. · ASX:RCEUS$75.90MUS$81.02Mn/an/an/an/an/an/an/a
Black Diamond Therapeutics, Inc. · NASDAQ:BDTXUS$75.28M−US$10.71Mn/an/an/a0.8×n/a0.2×1.76
Great Novel Therapeutics Biotech & Medicals Corp. · TPEX:7427US$73.93MUS$52.73Mn/a1,442×n/a3.2×n/a0.0×n/a
Pentixapharm Holding AG · XETR:PTPUS$73.87MUS$69.92Mn/a1,158×n/a2.4×n/a0.0×n/a
Faron Pharmaceuticals Oy · LSE:FARNUS$72.99MUS$57.36Mn/an/an/a5.7×n/a1.5×n/a
Kanaph Therapeutics Inc. · KRX:0082N0US$72.81MUS$39.07Mn/a9.3×n/a2.1×−729.8%0.0×n/a
Cellectis S.A. · EURONEXT:ALCLSUS$72.64M−US$9.64Mn/a−0.2×n/a1.8×−115.4%2.1×n/a
Eastwood Bio-Medical Canada Inc · TSXV:EBMUS$72.06MUS$72.05Mn/a127×n/an/a−28.5%n/a0.56
SynAct Pharma AB · OMXSTO:SYNACTUS$71.20MUS$71.51Mn/an/an/a5.1×n/a0.3×n/a
Bioton S.A. · GPW:BIOUS$70.63MUS$86.88Mn/a1.4×6.5×0.5×−3.3%0.1×n/a
Median of the othersUS$72.90MUS$63.64M68.3×6.5×2.2×−71.9%0.1×1.16

Team and board

Officers

OfficerRole
Nina WebsterChief Executive Officer / Managing Director
Mike TonroeChief Financial Officer & Company Secretary
Robert ShepherdChief Operating Officer
David FullerChief Medical Officer

Board

DirectorRole
Mark DiamondNon-Executive Chairman
Clinton SnowNon-Executive Director
Hugh AlsopNon-Executive Director
Sonia PoliNon-Executive Director

Events

QuarterResultsShare move
Q4 2025Aug 27, 2025−5.3%
Q2 2025Feb 24, 2025+1.0%
Q2 2023Feb 26, 2023 · After close−4.2%
Q4 2022Aug 28, 2022 · After close−12.5%
Q2 2022Feb 23, 2022 · After close−2.1%
Q4 2021Aug 15, 2021+42.5%
Q2 2021Feb 22, 2021−5.4%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (October 2026)Technical17 slidesOct 23, 2026
Canaccord Genuity Drug and Device Conference 2026Conference35 slidesOct 12, 2026
ASX SMIDcaps Conference 2026Conference16 slidesSep 23, 2026
E&P Healthcare Conference 2026Conference22 slidesSep 16, 2026
Investor Presentation (September 2026)Investor deck35 slidesSep 7, 2026
TechKnow Invest Roadshow (July 2026)Conference16 slidesJuly 2026
Investor Presentation (April 2026)Investor deck26 slidesApr 28, 2026
Euroz Hartleys Institutional Conference 2026Conference26 slidesMar 19, 2026
Investor Presentation (March 2026)Investor deck26 slidesMarch 2026
Oppenheimer 36th Annual Healthcare Life Sciences Conference (February 2026)Conference24 slidesFeb 26, 2026
Show 50 decks
DeckKindSlidesDate
J.P. Morgan Healthcare Conference 2026Conference27 slidesJan 15, 2026
Shareholder Meeting (November 2025)Shareholder meeting22 slidesNov 18, 2025
Canaccord Drug & Device Conference 2025Conference13 slidesOct 21, 2025
Ignite Investment Summit 2025Conference31 slidesOct 15, 2025
Biotech Showcase 2025Conference18 slidesSep 3, 2025
Investor Presentation (August 2025)Investor deck35 slidesAug 19, 2025
19th Bioshares Biotech Summit 2025Conference26 slidesAug 7, 2025
Investor Presentation (June 2025)Investor deck20 slidesJun 19, 2025
Monsoon Twilight Investor Briefing, Melbourne, May 2025Conference18 slidesMay 20, 2025
Corporate Update (May 2025)Corporate update17 slidesMay 1, 2025
Investor Presentation (February 2025)Investor deck29 slidesFeb 26, 2025
Euroz Hartleys Healthcare Forum 2025Conference34 slidesFeb 4, 2025
Investor Presentation (January 2025)Investor deck32 slidesJan 7, 2025
Investor Presentation (November 2024)Investor deck30 slidesNov 18, 2024
Shareholder Meeting (October 2024)Shareholder meeting24 slidesOct 1, 2024
Investor Presentation (August 2024)Investor deck36 slidesAugust 2024
Bio Connections Australia 2024Conference27 slidesJul 29, 2024
18th Bioshares Biotech Summit 2024Conference24 slidesJul 12, 2024
Investor Presentation (July 2024)Investor deck17 slidesJuly 2024
Monsoon Twilight Investor Briefing, Melbourne 2024Conference19 slidesJun 13, 2024
Investor Presentation (May 2024)Investor deck13 slidesMay 27, 2024
Investor Presentation (March 2024)Investor deck23 slidesMar 12, 2024
Investor Presentation (March 2024)Investor deck33 slidesMar 5, 2024
Euroz Hartley Healthcare Forum 2024Conference27 slidesFeb 6, 2024
Shareholder Meeting (November 2023)Shareholder meeting17 slidesNov 21, 2023
Investor Presentation (October 2023)Investor deck14 slidesOct 5, 2023
Investor Presentation (August 2023)Investor deck26 slidesAug 1, 2023
Bioshares Biotech Summit 2023Conference19 slidesJul 24, 2023
Investor Presentation (May 2023)Investor deck32 slidesMay 4, 2023
Emergence23 Wholesale Investor Conference 2023Conference13 slidesMar 22, 2023
Shareholder Meeting (November 2022)Shareholder meeting18 slidesNov 29, 2022
Investor Presentation (November 2022)Investor deck18 slidesNov 23, 2022
AusBiotech Invest 2022Conference14 slidesOct 27, 2022
Investor Presentation (September 2022)Investor deck38 slidesSep 15, 2022
16th Bioshares Biotech Summit 2022Conference23 slidesMay 12, 2022
Investor Presentation (March 2022)Investor deck27 slidesMar 29, 2022
Investor Presentation (March 2022)Investor deck15 slidesMar 1, 2022
Investor Presentation (February 2022)Investor deck25 slidesFeb 24, 2022
Investor Presentation (November 2021)Investor deck19 slidesNov 23, 2021
Shareholder Meeting (September 2021)Shareholder meeting18 slidesSep 27, 2021

This page holds 50 of 86 decks. Open Decks

Open Decks

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue4.35M1.25M583.5K36.8K6.46M4.44M2.34M1.45M845.3K554.6K
Cost of revenue138.2K56.0K50.5K44.6K13.5K4.68K6.42K1.52K
Gross profit4.21M1.25M583.5K36.8K6.41M4.39M2.33M1.44M838.9K553.1K
Research and development36.0M27.3M21.1M20.5M14.4M9.33M5.54M2.84M2.05M878.1K
Selling, general and administrative5.04M4.89M3.12M2.28M2.44M1.56M1.30M1.21M1.40M1.38M
Operating income-37.2M-36.3M-25.2M-22.8M-10.5M-10.9M-6.92M-4.33M-4.17M-2.31M
Depreciation and amortization138.2K123.6K48.7K56.0K50.5K44.6K13.5K4.68K6.42K1.52K
EBITDA-37.0M-36.2M-25.2M-22.8M-10.4M-10.9M-6.90M-4.33M-4.16M-2.31M
Interest expense1.16K00000
Income before tax-36.6M-31.7M-17.1M-13.8M-10.5M-10.1M-6.83M-4.32M-4.14M-2.29M
Income tax-6.74M-18.4M-7.93M-8.94M-6.03M-3.70M-2.34M-1.43M-825.0K-536.0K
Net income-29.8M-13.3M-17.1M-13.8M-10.5M-6.37M-4.49M-2.89M-3.32M-1.76M
Earnings per share, basic-0.05-0.02-0.04-0.04-0.04-0.03-0.03-0.02-0.03-0.02

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents16.2M68.3M22.1M7.99M9.63M5.25M7.79M3.56M6.28M2.24M
Receivables18.6M3.64M9.52M9.55M6.39M4.01M2.46M1.27M903.5K577.2K
Inventory184.3K400.6K118.5K107.6K-1.27M-903.5K-577.2K
Current assets35.1M72.2M31.9M17.8M16.5M9.42M10.4M4.94M7.26M2.87M
Property, plant and equipment117.6K162.4K6.41K8.61K1.42K1.23K2.62K3913.27K
Total assets58.6M91.2M32.1M17.8M16.5M9.42M10.4M4.94M7.26M2.87M
Accounts payable2.28M14.1M305.2K5.14M1.11M2.52M1.15M416.8K269.3K83.4K
Current liabilities9.18M22.2M3.36M11.8M2.02M7.95M2.63M737.8K406.7K242.1K
Total debt232.1K97.5K149.7K5.96M73.1K5.09M1.06M1.09M
Total liabilities73.3M77.8M13.9M11.8M2.07M7.95M2.63M737.8K406.7K242.1K
Shareholders' equity-14.8M13.4M18.2M5.96M14.4M1.47M7.76M4.20M6.86M2.63M
Shares outstanding600.3M560.4M452.9M325.5M299.5M201.4M174.6M161.4M117.5M86.8M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-51.8M39.1M-7.00M-12.7M-13.4M-6.46M-4.72M-2.75M-3.23M-1.86M
Capital spending-4.98K-21.0K-15.8K-2.30K-10.6K-9.57K-9.57K-6.91K-3.54K-2.58K
Free cash flow-51.8M39.0M-7.02M-12.7M-13.4M-6.47M-4.72M-2.76M-3.23M-1.87M
Cash from investing-4.98K-21.0K-15.8K-2.30K-10.6K4.38K4.38K-6.91K-3.54K-2.58K
Cash from financing118.5K7.42M21.2M11.1M17.7M3.83M8.91M8.91M7.25M2.09M
Dividends paid-10.7M-1.40K-1.24M-8.48M
Share buybacks7.55M-1.40M-444.6K-1.24M-1.24M-441.4K-441.4K-371.5K-128.1K
Change in cash-52.1M46.1M14.1M-1.64M4.38M-2.54M4.22M-2.72M4.04M225.8K

Open Financials

Filings

FilingDateTypeFiled with
Final Director's Interest Notice - MDNov 5, 2026Ownership change noticeASX
Dimerix Quarterly Activities Report and Appendix 4COct 28, 2026Quarterly reportASX
Dimerix Quarterly Activities Report and Appendix 4COct 28, 2026Quarterly reportASX
New Data Supports Biological Rationale for DMX-200 in FSGSOct 22, 2026Other filingsASX
2026 AGM Notice of Meeting, Letter of Access and Proxy FormOct 21, 2026Meeting noticeASX
Dimerix Announces Board Chair TransitionOct 18, 2026Management or board changeASX
DMX-200 First 100 Patients Complete Phase 3 Trial TreatmentOct 15, 2026Operations updateASX
Dimerix at Canaccord Drug & Device and Ignite ConferencesOct 11, 2026Operations updateASX
First Patient Reaches Four Years in DMX-200 Clinical ProgramOct 4, 2026Other filingsASX
Notification regarding unquoted securities - DXBSep 28, 2026Other filingsASX
Show 200 filings
FilingDateTypeFiled with
Notification of 2026 Annual General Meeting DateSep 25, 2026Meeting noticeASX
Dimerix Draws Down A$17M Under Non-Dilutive Funding FacilitySep 22, 2026FinancingASX
Dimerix Presents at ASX SMIDcaps Conference 2026Sep 22, 2026Other filingsASX
Waiver of Listing Rule 10.1 GrantedSep 22, 2026Other filingsASX
Dimerix Presents at E&P Healthcare Conference 2026Sep 15, 2026Other filingsASX
Dimerix DMX-652 Granted Mexican Composition of Matter PatentSep 13, 2026Other filingsASX
Dimerix Investor PresentationSep 6, 2026Other filingsASX
S&P DJI Announces September 2026 Quarterly RebalanceSep 4, 2026Other filingsASX
Dimerix Secures A$34 Million Non-Dilutive Funding FacilitySep 3, 2026FinancingASX
Trading HaltSep 1, 2026Trading halt or suspensionASX
Appendix 4E and 2026 Annual ReportAug 26, 2026Annual reportASX
Appendix 4G and Corporate Governance StatementAug 26, 2026Other filingsASX
Dimerix Receives US$10M Upfront Payment from EverestAug 19, 2026Other filingsASX
Dimerix Assumes Sponsorship of US IND for New Asset DMX-652Aug 16, 2026Other filingsASX
Dimerix Presents at Bioshares Summit 2026Aug 5, 2026Other filingsASX
Dimerix Quarterly Activities Report and Appendix 4CJul 29, 2026Quarterly reportASX
US Patent Granted for Dimerix New Asset DMX-652Jul 22, 2026Other filingsASX
Dimerix Expands Pipeline with Acquisition of Phase 2 AssetJul 16, 2026Acquisition or disposalASX
Dimerix Non-Dilutive Funding Builds Pipeline, Boosts RunwayJul 16, 2026FinancingASX
DMX-200 Available To Patients Via Post-Trial Access PathwaysJul 8, 2026Operations updateASX
Dimerix Licenses DMX200 to Everest for China and Asia RegionJun 15, 2026Other filingsASX
Dimerix Quarterly Activities Report and Appendix 4CApr 29, 2026Quarterly reportASX
ACTION3 Statistical Review CompleteApr 27, 2026Other filingsASX
Dimerix to Conduct Review of ACTION3 Statistical AssumptionsMar 15, 2026Other filingsASX
Dimerix Phase 3 Trial Last Patient Receives First DoseMar 9, 2026Operations updateASX
Appendix 4D and Half Year Financial ReportFeb 25, 2026Interim reportASX
Quarterly Appendix 4C and Activities ReportJan 28, 2026Quarterly reportASX
BioMarin to acquire Dimerix US Partner, Amicus TherapeuticsDec 21, 2025Acquisition or disposalASX
DMX-200 ACTION3 Phase 3 Trial Completes RecruitmentDec 14, 2025Operations updateASX
Successful Completion of Planned IDMC ReviewNov 18, 2025Other filingsASX
Successful PARASOL Collaboration Data Analysis OutcomeOct 7, 2025Other filingsASX
DMX-200 receives Orphan Drug Designation in JapanSep 29, 2025Other filingsASX
Appendix 4E and 2025 Annual ReportAug 27, 2025Annual reportASX
Dimerix receives 1st Development Milestone payment from FUSOJun 29, 2025Other filingsASX
ACTION3 Clinical Trial Milestone Recruitment UpdateJun 12, 2025Other filingsASX
1st ACTION3 site in Japan activated and milestone triggeredMay 29, 2025Other filingsASX
Successful planned IDMC review of ACTION3 trialMay 21, 2025Other filingsASX
Dimerix receives initial upfront payment from AmicusMay 5, 2025Other filingsASX
Investor Webinar and PresentationApr 30, 2025Other filingsASX
Dimerix Licenses DMX-200 in the USApr 30, 2025Other filingsASX
Trading HaltApr 28, 2025Trading halt or suspensionASX
FDA confirms Proteinuria as Primary Endpoint for US approvalApr 27, 2025Operations updateASX
S&P DJI Announces March 2025 Quarterly RebalanceMar 7, 2025Other filingsASX
Dimerix receives initial upfront payment from FUSOMar 3, 2025Acquisition or disposalASX
Half-Year Financial Report & Appendix 4D - 31 December 2024Feb 24, 2025Interim reportASX
First Paediatric Patient Recruited for ACTION3Jan 15, 2025Other filingsASX
Dimerix enters Development and License Agreement for JapanJan 6, 2025Other filingsASX
DMX-200 ACTION3 Phase 3 Trial Part 2 Recruitment CompleteDec 29, 2024Other filingsASX
Dimerix Receives $7.9M R&D Tax Incentive RebateNov 14, 2024Other filingsASX
NEPTUNE Study Network to Enhance Phase 3 Recruitment in USOct 31, 2024Other filingsASX
Project PARASOL Update & Medical Advisory Board AppointmentOct 27, 2024Operations updateASX
ACTION3 Trial Recruitment and Multiregion Trial Site UpdateSep 15, 2024Operations updateASX
First Paediatric Site Activated and Trial UpdateSep 11, 2024Other filingsASX
First patient enters into Open Label Extension studySep 10, 2024Other filingsASX
Preliminary Final ReportAug 28, 2024ResultsASX
Adolescent Recruitment into ACTION3 Clinical TrialJul 3, 2024Other filingsASX
Dimerix and Taiba enter into License Agreement for DMX-200May 26, 2024Other filingsASX
Dimerix Receives PIP Approval from the UK MHRAApr 30, 2024Other filingsASX
Dimerix Completes $20M PlacementMar 11, 2024FinancingASX
Dimerix Successfully Passes Efficacy Interim AnalysisMar 10, 2024Operations updateASX
PH3 Data Collection Complete for First Interim AnalysisFeb 26, 2024Other filingsASX
Half-Year Financial Report & Appendix 4D - 31 December 2023Feb 25, 2024Interim reportASX
ACTION3 IND Approved in ChinaNov 27, 2023Operations updateASX
Dimerix Receives Initial Upfront Payment from Advanz PharmaNov 5, 2023Other filingsASX
Dimerix Announces License Agreement for EU, Canada, ANZOct 4, 2023Other filingsASX
FDA Approves Qytovra Brand NameSep 24, 2023Operations updateASX
Regulatory Approval received in Malaysia for ACTION3 StudySep 21, 2023Other filingsASX
Dimerix Receives $8.9M R&D Tax Incentive RebateSep 12, 2023Other filingsASX
Successful Completion of 2nd DSMB Review of FSGS TrialAug 7, 2023Other filingsASX
DMX-200 FSGS PH3 Kidney Trial Part 1 Outcome set for Q1 CY24Jul 23, 2023Other filingsASX
Approval received for Paediatric Investigation Plan from EMAJul 4, 2023Legal or regulatory actionASX
Dimerix confirms Phase 3 study design appropriate for ChinaJul 2, 2023Other filingsASX
ProspectusJun 26, 2023Offer documentASX
Dimerix Announces Update on Successful Capital RaiseJun 5, 2023Other filingsASX
Rights Issue ProspectusMay 4, 2023FinancingASX
Reinstatement to Official QuotationMay 3, 2023Trading halt or suspensionASX
Entitlement offer and Convertible Note to raise $12 millionMay 3, 2023FinancingASX
Voluntary SuspensionMay 2, 2023Trading halt or suspensionASX
Half-Year Financial Report & Appendix 4D - 31 December 2022Feb 26, 2023Interim reportASX
DXB to Receive $2.8m in Prepayment of R&D Tax IncentiveFeb 16, 2023Other filingsASX
Successful Completion of DSMB Review of Phase 3 FSGS TrialFeb 8, 2023Other filingsASX
FDA Confirms Inclusion of Paediatrics in ACTION3 StudyJan 11, 2023Other filingsASX
DMX-200 FSGS Phase 3 Trial Part 1 Recruitment AchievedDec 14, 2022Other filingsASX
CLARITY 2.0 COVID-19 Study OutcomeDec 12, 2022Other filingsASX
Chair address and CEO presentation to AGMNov 28, 2022Other filingsASX
Dimerix Receives A$6.0M R&D Tax Incentive RebateOct 24, 2022Other filingsASX
Appendix 4E and 2022 Annual ReportAug 28, 2022Annual reportASX
CLARITY 2.0 COVID-19 Study Concludes RecruitmentAug 17, 2022Other filingsASX
New Patent Family Application for DMX-700Aug 8, 2022Other filingsASX
DMX-700 Study Shows Significant 80% Reduction in Lung InjuryJul 3, 2022Other filingsASX
REMAP-CAP COVID-19 Study Analysis UpdateJun 26, 2022Other filingsASX
New Clinical Trial for DMX-200 in Diabetic Kidney DiseaseJun 6, 2022Other filingsASX
Phase 3 FSGS Kidney Trial First Patient RecruitedMay 30, 2022Other filingsASX
Dimerix presentation at Bioshares Biotech SummitMay 11, 2022Other filingsASX
FDA IND Approval for Phase 3 Study of DMX-200 in FSGSMay 8, 2022Other filingsASX
Dimerix Receives A$3.7M R&D Tax Incentive RebateMar 28, 2022Other filingsASX
DSMB Change to REMAP-CAP COVID-19 StudyFeb 27, 2022Other filingsASX
Half-Year Financial Report & Appendix 4D - 31 December 2021Feb 23, 2022Interim reportASX
First Regulatory Approval in Europe for DMX-200 FSGS StudyFeb 1, 2022Other filingsASX
Patients Dosed in DMX-200 COVID-19 Phase 3 Study in IndiaJan 10, 2022Other filingsASX
Ethics Approval in Australia for Phase 3 COVID-19 StudyDec 22, 2021Other filingsASX
DSMB Recommends Continuation of Ph3 COVID-19 Study in EuropeDec 16, 2021Other filingsASX
Pause in TradingDec 15, 2021Trading halt or suspensionASX
First Approvals Received for Start of Phase 3 FSGS TrialOct 20, 2021Other filingsASX
Phase 3 DMX-200 COVID-19 Study Expands into AustraliaOct 14, 2021Other filingsASX
Dimerix Closes SPP OversubscribedSep 30, 2021Other filingsASX
DMX-200 CLARITY COVID-19 Study Approval in IndiaSep 24, 2021Other filingsASX
Phase 3 Study in FSGS Kidney Patients CommencesAug 24, 2021Other filingsASX
SPP and Options ProspectusAug 23, 2021Offer documentASX
Response to ASX QueryAug 19, 2021Explanation requestASX
Successful $20m Placement to Fund Phase 3 TrialsAug 15, 2021FinancingASX
DMX-200 COVID-19 Study Opens More Sites in Europe and UKAug 1, 2021Other filingsASX
FDA Confirms Phase 3 Study Design in FSGS Kidney DiseaseJul 18, 2021Other filingsASX
Dimerix Receives Innovation Passport and ILAP DesignationJun 6, 2021Other filingsASX
Dimerix Confirms Phase 3 FSGS Study Design With EMAJun 3, 2021Other filingsASX
DMX-200 Remains Eligible for Accelerated ApprovalMay 27, 2021Other filingsASX
COVID-19 Study Recruits Multiple Patients in EuropeApr 22, 2021Other filingsASX
Major Shareholder Loan for $5 MillionMar 29, 2021Other filingsASX
Clinical Study in Patients with COVID-19 ProgressesMar 24, 2021Other filingsASX
DMX-200 Competitive Position Further EnhancedMar 23, 2021Other filingsASX
CLARITY 2.0 Study Progresses In Patients With COVID-19Mar 9, 2021Other filingsASX
Appendix 4D and Interim Financial ReportFeb 21, 2021Interim reportASX
Dimerix Plans for Next Study in Diabetic Kidney DiseaseJan 27, 2021Other filingsASX
Second Study to Include DMX-200 in COVID-19 PatientsNov 29, 2020Other filingsASX
ARDS in COVID-19 Patients Protocol PublishedNov 8, 2020Other filingsASX
Positive Additional Data to Support DMX-200 DevelopmentOct 26, 2020Other filingsASX
Receipt of R&D Tax IncentiveOct 20, 2020Other filingsASX
DMX-700 Data Demonstrates Effect on Key COPD ReceptorsOct 6, 2020Other filingsASX
Positive Top-Line Results in DKD Phase 2 Clinical StudySep 13, 2020Other filingsASX
Dimerix Awarded $1 Million MRFF FundingSep 2, 2020Other filingsASX
Positive Top-Line Results in FSGS Phase 2a Clinical StudyJul 28, 2020Other filingsASX
Last Patient Completes Dosing in DKD Phase 2 Clinical StudyJul 23, 2020Other filingsASX
Dimerix Completes $5.8m PlacementJun 22, 2020FinancingASX
Last Patient Completes Dosing in FSGS Phase 2 Clinical StudyJun 16, 2020Other filingsASX
Global REMAP-CAP Platform Trial Protocol To Include DMX-200Jun 3, 2020Other filingsASX
R&D Tax Incentive FacilityApr 2, 2020Other filingsASX
DMX-200 Treatment Continued Under TGA Special Access SchemeMar 2, 2020Other filingsASX
Half Yearly Report and AccountsFeb 18, 2020Interim reportASX
Quarterly Commentary & Appendix 4CJan 20, 2020Quarterly reportASX
DMX-200 Clinical Trial UpdateJan 6, 2020Other filingsASX
Dimerix Completes $2.5m PlacementDec 2, 2019FinancingASX
Dimerix Holds Pre-IND Meeting on DMX-200 With FDANov 24, 2019Other filingsASX
New Drug Pipeline Candidate DMX-700 & Company UpdateOct 9, 2019Other filingsASX
DMX-200 Phase 2 Clinical Study in DKD Completes RecruitmentSep 25, 2019Other filingsASX
DMX-200 Phase 2 Clinical Trial in FSGS Fully RecruitedJul 9, 2019Other filingsASX
DMX-200 Clinical UpdateJun 25, 2019Other filingsASX
Dimerix Signs Licence Agreement for Receptor-HIT TechnologyJun 23, 2019Other filingsASX
DMX-200 Manufacturing UpdateMay 26, 2019Other filingsASX
Appendix 4C - quarterlyApr 26, 2019Quarterly reportASX
Appendix 4C and Quarterly HighlightsJan 30, 2019Quarterly reportASX
Dimerix Receives R&D Tax Cash Rebate Totalling $1.07mDec 19, 2018Other filingsASX
1st Patient Dosed in DMX-200 Clinical Trial for FSGSNov 21, 2018Other filingsASX
DXB Receives Orphan Drug Designation in EUNov 20, 2018Other filingsASX
FIRST PATIENT DOSED IN DMX-200 CLINICAL TRIALNov 19, 2018Other filingsASX
EXECUTIVE TEAM BOLSTERED THROUGH CEO & MD APPOINTMENTAug 26, 2018Other filingsASX
Quarterly Review & Appendix 4CJul 31, 2018Quarterly reportASX
Ethics Approval Received Appendix 3B and S.708A NoticeJul 18, 2018FinancingASX
Further US patent allowed for DMX-200Jul 1, 2018Other filingsASX
Dual Phase 2 trials launched for CKDMay 14, 2018Other filingsASX
Westar Capital Retained as Corporate AdvisorsApr 12, 2018Other filingsASX
CMO Appointment and Clinical Trials UpdateMar 26, 2018Other filingsASX
Half Year Report and Financial StatementsFeb 26, 2018Interim reportASX
Oversubscribed Placement to Raise a Further $4.5mFeb 20, 2018FinancingASX
Quarterly Review and Appendix 4CJan 29, 2018Quarterly reportASX
Results of Entitlement OfferJan 23, 2018FinancingASX
DMX-200 Dosage Optimisation Study Successfully CompletedJan 7, 2018Other filingsASX
Proteomics partnership to improve treatment of CKDDec 13, 2017Other filingsASX
Entitlement Offer BookletDec 5, 2017FinancingASX
Entitlement Offer to raise $5.5 millionDec 5, 2017FinancingASX
Suspension from Official QuotationDec 4, 2017Trading halt or suspensionASX
Dimerix Phase 2a Subgroup Analysis ResultsNov 1, 2017Other filingsASX
Ethics Committee Approval for Pharmacokinetic TrialOct 23, 2017Other filingsASX
Dimerix Receives $545k R&D Tax RefundOct 17, 2017Other filingsASX
Notice of Annual General Meeting/Proxy FormSep 12, 2017Meeting noticeASX
DMX-200 tablet manufacture and human study timelineSep 4, 2017Other filingsASX
Positive Results from Phase 2a Trial of DMX-200Jul 12, 2017Other filingsASX
Research Validates Relevance of DMX Receptor-HIT TechnologyJun 12, 2017Other filingsASX
Investor UpdateApr 10, 2017Other filingsASX
Receipt of $420k Research & Development Tax RefundMar 21, 2017Other filingsASX
Corporate PresentationFeb 13, 2017Other filingsASX
Key Patent Allowed in JapanJan 30, 2017Other filingsASX
Dimerix Raises $2 million to Advance Clinical ProgramJan 24, 2017Other filingsASX
Recruitment of Part A of Phase 2 Trial of DMX-200 CompletedDec 5, 2016Other filingsASX
Appointment of Chief Executive OfficerNov 6, 2016Management or board changeASX
Update presentation - interim dataOct 11, 2016Other filingsASX
Positive interim analysis of DMX-200 phase II dataOct 3, 2016Other filingsASX
Appendix 4EAug 24, 2016ResultsASX
Response to ASX Price and Volume QueryAug 15, 2016Explanation requestASX
Outcomes of DMX-200 pre-IND meeting with the FDAAug 1, 2016Other filingsASX
Update for NASH Pre-Clinical ProgramJul 28, 2016Other filingsASX

This page holds 200 of 242 filings. Open Filings

Open Filings

Cap table

Built by 6ix from Dimerix Limited’s releases

Common shares
600,396,776
Fully diluted
600,396,776

Fully diluted

LineShares
Common shares600,396,776

Share count over time

CountShares
Nov 22, 2026600,396,776

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Clinton SnowNon-Executive Director · Since at least Nov 5, 2026
David FullerChief Medical Officer · Since at least Apr 28, 2026
Hugh AlsopNon-Executive Director · Since at least Nov 5, 2026
Mark DiamondNon-Executive Chairman · Since at least Nov 5, 2026
Mike TonroeChief Financial Officer & Company Secretary · Since at least Nov 4, 2026
Nina WebsterChief Executive Officer / Managing Director · Since at least Sep 22, 2026
Robert ShepherdChief Operating Officer · Since at least Nov 5, 2026
Sonia PoliNon-Executive Director · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Dimerix Limited.